What Researchers Did
The authors reviewed experimental and clinical research on using hyperbaric oxygen therapy (HBOT) alongside standard treatment for glioblastoma multiforme (GBM), an aggressive brain tumor.
What They Found
This review of experimental and clinical research found that HBOT was well tolerated in GBM patients and did not significantly increase toxicity when added to treatment. The abstract describes the clinical trials as limited. Those trials and preclinical studies suggest that radiotherapy given immediately after HBOT enhances the effects of radiotherapy in some aspects. HBOT also appeared able to strengthen the anti-tumor effect of chemotherapy when the two were applied together. HBOT used by itself as a curative strategy against GBM is controversial in preclinical studies and has not been evaluated rigorously in GBM patients. The abstract reports no sample sizes, pressures or session counts.
What This Means for Canadian Patients
For people facing GBM, this review suggests HBOT has been studied only as an add-on to radiotherapy and chemotherapy, not as a stand-alone cure. The evidence it describes is limited, and the abstract says HBOT alone has not been rigorously tested in patients. Anyone considering HBOT alongside cancer treatment should talk with their oncology team first.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The review rests on limited clinical trials and preclinical studies, and the abstract states that HBOT alone has not been evaluated rigorously in GBM patients.